A detailed history of Bank Of America Corp transactions in Lantern Pharma Inc. stock. As of the latest transaction made, Bank Of America Corp holds 69 shares of LTRN stock, worth $257. This represents 0.0% of its overall portfolio holdings.

Number of Shares
69
Holding current value
$257
% of portfolio
0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$3.91 - $9.51 $269 - $656
69 New
69 $0
Q4 2023

Feb 14, 2024

BUY
$2.48 - $4.39 $12 - $21
5 New
5 $0
Q4 2022

Feb 10, 2023

BUY
$4.19 - $6.04 $33 - $48
8 New
8 $0
Q1 2022

May 16, 2022

SELL
$5.6 - $8.22 $72 - $106
-13 Closed
0 $0
Q4 2021

Feb 08, 2022

SELL
$7.11 - $11.04 $39,744 - $61,713
-5,590 Reduced 99.77%
13 $0
Q3 2021

Nov 15, 2021

BUY
$10.53 - $14.93 $35,928 - $50,941
3,412 Added 155.73%
5,603 $62,000
Q2 2021

Sep 13, 2021

BUY
$12.94 - $19.89 $28,351 - $43,578
2,191 New
2,191 $32,000

Others Institutions Holding LTRN

About Lantern Pharma Inc.


  • Ticker LTRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 10,830,900
  • Market Cap $40.4M
  • Description
  • Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...
More about LTRN
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.